Netris Pharma presented positive phase Ib data for NP-137, its first-in-class netrin-1 inhibitor, aimed at reducing chemotherapy resistance in pancreatic cancer. The results suggest the drug can improve responsiveness when paired with chemotherapy—an area where resistance has remained a central clinical challenge. The company’s update positions netrin-1 as a pathway to modulate the tumor environment and overcome resistance mechanisms that limit the durability of existing regimens. For the broader pipeline, the data reinforce continued interest in signaling-axis inhibitors beyond classic cytotoxics. If additional studies confirm benefit and define biomarker strategies, NP-137 could become a candidate for combination expansion in PDAC lines of therapy.